Olaparib is a newly approved poly (ADP-ribose) polymerase (PARP) inhibitor, indicated for the treatment of cancers that exhibit DNA repair defects, including BRCA1/2-mutated breast cancers. This evidence concerns the gene BRCA1 and breast carcinoma.